miércoles, 2 de diciembre de 2015

Talimogene Laherparepvec - National Cancer Institute

Talimogene Laherparepvec - National Cancer Institute

National Cancer Institute



National Cancer Institute





Talimogene Laherparepvec

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
(tah-LIH-moh-jeen lah-HER-pah-REP-vek)
This page contains brief information about talimogene laherparepvec and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Imlygic
FDA Approved
Yes

Use in Cancer

Talimogene laherparepvec is approved to treat:
  • Melanoma in the skin and lymph nodes that cannot be removed by surgery. It is used as local treatment in patients whose disease has recurred (come back) after being treated with surgery.
Talimogene laherparepvec is also being studied in the treatment of other types ofcancer.

More About Talimogene Laherparepvec

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results

Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Talimogene Laherparepvec - Check for trials from NCI's list of cancer clinical trials now accepting patients.

No hay comentarios:

Publicar un comentario